VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
131 hedge funds and large institutions have $191M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 35 reducing their positions, and 18 closing their positions.
162% more call options, than puts
Call options by funds: $1M | Put options by funds: $383K
31% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 35
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
2% less funds holding
Funds holding: 134 → 131 (-3)
26% less capital invested
Capital invested by funds: $260M → $191M (-$68.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$6.33M |
| 2 |
Morgan Stanley
New York
|
+$1.23M |
| 3 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$932K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$627K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$532K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.93M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.37M |
| 3 |
Citigroup
New York
|
-$783K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$404K |
| 5 |
Goldman Sachs
New York
|
-$247K |
VBIV Hedge Fund Activity: Q1 2022 in Review
131 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q1 2022, worth a combined $191M — down 26% from $260M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VBIV and 17 opened new positions — a net loss of 1 holder — while 35 trimmed existing stakes and 46 added.
The largest buyer was State Street, adding an estimated $6.33M. The largest seller was Millennium Management, cutting an estimated $1.93M.
- 131 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q1 2022, down from 134 in Q4 2021.
- Funds reported $191M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q1 2022, down 26% quarter-over-quarter.
- 17 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q1 2022 and 18 closed out, a net change of -1 holder.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q1 2022 was State Street, an estimated $6.33M added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q1 2022 was Millennium Management, an estimated $1.93M sold.
Based on aggregated 13F filings for Q1 2022.